The National Institutes of Health today announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing schizophrenia.

NIH’s Accelerating Medicines Partnership program will administer AMP Schizophrenia to leverage resources and expertise from NIH, the Food and Drug Administration and multiple non-profit and private organizations. Their goal is to identify promising biological markers that can help identify those at risk of developing schizophrenia as early as possible, track the progression of symptoms and other outcomes, and define targets for treatment development.

The initiative also will seek to develop measures that further define early stages of risk while predicting the likelihood of progression to psychosis and other outcomes.

 

Related News Articles

Headline
The deadline for health delivery organizations to apply for the AHA’s 2026 Foster G. McGaw Prize is 1 p.m. ET May 6. The award honors organizations that…
Headline
A study published March 31 by the National Institutes of Health found that adults living in rural areas have worse cardiovascular health than those in urban…
Headline
Cigarette smoking by adults has dropped to its lowest level in 60 years, the Centers for Disease Control and Prevention reported today. Despite that, tobacco…
Headline
In this conversation, Mindy Estes, M.D., former CEO of Saint Luke's Health System and former AHA board chair, and Roxanna Gapstur, R.N., CEO of WellSpan Health…
Headline
A case study by the AHA's Community Health Improvement network explains how Children’s Mercy Kansas City created a new model to coordinate its community…
Chairperson's File
Trust — in one another, in our field, and in our communities — is so important to what we do. Everyone should know that our hospitals and health systems are a…